Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW685698X & GW642444M · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| arm 1 | EXPERIMENTAL | study drug |
| Name | Type | Description |
|---|---|---|
| GW685698X & GW642444M | DRUG | study drug |
Inclusion criteria: * Healthy adults aged between 18 and 60 years. * Male subjects or female subjects of non child bearing potential. * Body weight at least 50 kg and BMI within the range of 19-31 kg/m2 inclusive. * No significant abnormality from ECG at screening. * FEV1 at least 90% predicted and...
GW685698X & GW642444M is an investigational small molecule combination being developed for asthma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The combination is being studied for its potential use in treating asthma, though it remains in early-stage clinical trials.
GW685698X & GW642444M is being developed by GSK plc, a pharmaceutical company traded on the stock exchange under the ticker GSK. The company is conducting clinical research on this combination therapy for asthma, with the drug currently in Phase 1 development.
GW685698X & GW642444M is in Phase 1 clinical development. It is an investigational drug and has not been approved for use. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for asthma.
GW685698X & GW642444M has one completed clinical trial, registered as NCT00538057. This Phase 1 study compared the two respiratory drugs when used in combination and separately from a novel inhaler device in healthy subjects. The trial enrolled 16 participants in Australia and was completed.
GW685698X & GW642444M is a combination of two drugs, GW685698X and GW642444M, studied together as a single investigational therapy. The clinical trial NCT00538057 compared the combination against each drug used separately, all administered from a novel inhaler device.